DIWALI SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim Offer →
logo

AMANTA vs BETA: Stock Comparison

AMANTA HEALTHCARE vs BETA DRUGSUpdated 6 Nov 26, 4:08 PM ISTNSE & company filings

BETA DRUGS is the larger company by market capitalisation. AMANTA HEALTHCARE shows faster revenue growth, while BETA DRUGS shows a lower P/E, a higher ROE and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AMANTA leads 2; BETA leads 10 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AMANTABETA

Valuation lens

What price are you paying?

Market CapContext only
₹757 Cr
₹2,011 Cr
P/E RatioBETA has the lower reading
42.91x
35.56x ✓
P/B RatioAMANTA has the lower reading
2.86x ✓
4.19x
EPSBETA has the higher reading
₹0.85
₹18 ✓
Book ValueContext only
₹56.71
₹220.09
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
BETA is the larger company
₹2,011 Cr vs ₹757 Cr
P/E Ratio
BETA has a lower P/E
35.56x vs 42.91x
P/B Ratio
AMANTA has a lower P/B
2.86x vs 4.19x
EPS
BETA has higher earnings per share
₹18 vs ₹0.85
Revenue Growth (TTM YoY)
AMANTA has faster revenue growth
6.8% vs 0%
EPS Growth (TTM YoY)
BETA has faster EPS growth
0% vs -23.4%
Qtr Sales Growth
BETA has stronger quarterly sales growth
9.51% vs -10.64%
Qtr Profit Growth
BETA has stronger quarterly profit growth
16.98% vs -40.15%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAMANTABETA
SectorHealthcare—
IndustryPharmaceuticals—

Price

MetricAMANTABETA
Live Price₹195.28₹1,805.9
Day Change-0.43%-1.89%
Volume94,23015,899
52-Week High₹199.5₹2,807.9
52-Week Low₹92₹990.1
Distance from 52W High-2.12%-35.69%

Valuation

MetricAMANTABETA
Market Cap₹757 Cr₹2,011 Cr
P/E Ratio42.91x35.56x
P/B Ratio2.86x4.19x
EPS₹0.85₹18
Book Value₹56.71₹220.09
Dividend Yield0%0%

Growth

MetricAMANTABETA
Revenue Growth (TTM YoY)6.8%0%
EPS Growth (TTM YoY)-23.4%0%
Qtr Sales Growth-10.64%9.51%
Qtr Profit Growth-40.15%16.98%

Profitability & Leverage

MetricAMANTABETA
ROE6.75%14.79%
ROCE7.89%18.03%
Net Margin5.17%10.78%
Operating Margin14.55%16.79%
Debt to Equity1.06x0.6x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricAMANTABETA
Promoter Holding31.33%▲ 4.46 pp58.91%▼ 0.19 pp
FII Holding0.07%▼ 0.36 pp1.37%▲ 0.35 pp
DII Holding12.2%▼ 0.72 pp6.45%▲ 0.22 pp
Public Holding23.93%▲ 1.08 pp33.27%▼ 0.38 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AMANTA HEALTHCARE and BETA DRUGS.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.